Publications by authors named "Peter Stopfer"

Claim this Profile
I
In vitro transporter substrate properties of previously reported biomarkers for renal OAT1/OAT3-mediated drug-drug interactions.
Jana Picurová, Arne Gessner, Nora Bartels, Sofie Scheuerlein, Oliver Fischer, Peter Stopfer

Biochem Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs.
Karine Rodriguez-Fernandez, José David Gómez-Mantilla, Suneet Shukla, Peter Stopfer, Peter Sieger

Clin Pharmacokinet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans.
Arne Gessner, Jörg König, Pia Wenisch, Markus R Heinrich, Peter Stopfer

Clin Pharmacol Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the Working Models for Drug-Drug Interactions: Impact on Preclinical and Clinical Drug Development.
James Nguyen, David Joseph, Xin Chen, Beshoy Armanios, Ashish Sharma, Peter Stopfer

Pharmaceutics· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond CL and V: A comprehensive approach to human pharmacokinetic predictions.
Anneke Himstedt, Hermann Rapp, Peter Stopfer, Ralf Lotz, Stefan Scheuerer

Drug Discov Today· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis.
Rolf Grempler, Jennifer Ahlberg, Eva Germovsek, Priyanka Gupta, Hua Li, Peter Stopfer

Adv Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Metabolomic Analysis of Sensitivity and Specificity of 23 Previously Proposed Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions.
Arne Gessner, Fabian Müller, Pia Wenisch, Markus R Heinrich, Jörg König, Peter Stopfer

Clin Pharmacol Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N -Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid.
Fabian Müller, Kathrin Hohl, Sascha Keller, Sven Schmidt-Gerets, Birgit Deutsch, Peter Stopfer

Clin Pharmacol Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Nina Hanke, José David Gómez-Mantilla, Naoki Ishiguro, Peter Stopfer, Valerie Nock

Pharm Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine.
Sabrina T Wiebe, Thomas Giessmann, Kathrin Hohl, Sven Schmidt-Gerets, Edith Hauel, Peter Stopfer

Clin Pharmacokinet· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug-Drug-Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals.
Nina Hanke, Denise Türk, Dominik Selzer, Naoki Ishiguro, Thomas Ebner, Peter Stopfer

Clin Pharmacokinet· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.
Hannah Britz, Nina Hanke, Mitchell E Taub, Ting Wang, Bhagwat Prasad, Peter Stopfer

Pharm Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies.
Nina Hanke, Denise Türk, Dominik Selzer, Sabrina Wiebe, Éric Fernandez, Peter Stopfer

Pharmaceutics· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Sven Wind, Ulrike Schmid, Matthias Freiwald, Kristell Marzin, Ralf Lotz, Peter Stopfer

Clin Pharmacokinet· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
Peter Stopfer, Thomas Giessmann, Kathrin Hohl, Sabine Hutzel, Sven Schmidt

Br J Clin Pharmacol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.
Peter Stopfer, Thomas Giessmann, Kathrin Hohl, Ashish Sharma, Naoki Ishiguro

Eur J Drug Metab Pharmacokinet· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Sven Wind, David Schnell, Thomas Ebner, Matthias Freiwald, Peter Stopfer

Clin Pharmacokinet· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer.
Claudia Dallinger, Dirk Trommeshauser, Kristell Marzin, Andre Liesener, Rolf Kaiser, Peter Stopfer

J Clin Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.
Chooi Peng Lee, N Jane Taylor, Gerhardt Attard, Simon Pacey, Paul D Nathan, Peter Stopfer

Oncologist· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.
Jean-Pierre Droz, Jaques Medioni, Christine Chevreau, Helene De Mont-Serrat, Michael Merger, Peter Stopfer

Anticancer Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
David Schnell, Susanne Buschke, Holger Fuchs, Dietmar Gansser, Rainer-Georg Goeldner, Peter Stopfer

Cancer Chemother Pharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.
Klaus Mross, Martin Büchert, Annette Frost, Michael Medinger, Peter Stopfer

BMC Cancer· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
Matthias Freiwald, Ulrike Schmid, Angele Fleury, Sven Wind, Peter Stopfer

Cancer Chemother Pharmacol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.
Sven Wind, Thomas Giessmann, Arvid Jungnik, Tobias Brand, Kristell Marzin, Peter Stopfer

Clin Drug Investig· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
L Rhoda Molife, Sarah M Rudman, Salma Alam, Daniel S-W Tan, Hartmut Kristeleit, Peter Stopfer

Cancer Chemother Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis